Result for
Topic: Vaccines and Immunity
December 11, 2020
Intention of health care workers to accept COVID-19 vaccination and related factors: a systematic review and meta-analysis
[Pre-print, not peer reviewed] In a systematic review examining the intention of healthcare workers (HCW) to accept COVID-19 vaccination (11 studies, 8,847 HCWs), the overall proportion of HCWs that intend to accept COVID-19 vaccination was 56% (95% CI 44-68%) with a wide range among studies from 28% to 82%. Factors associated with increased HCW willingness…
December 10, 2020
Safety and Efficacy of the BNT162b2 MRNA Covid-19 Vaccine
Results of the phase 3 double-blind, randomized, placebo-controlled trial for the BioNTech and Pfizer mRNA vaccine BNT162b2 (n=21,720 in vaccine group, and 21,728 in placebo group) showed a vaccine efficacy of 95% (95% CI 90.3-97.6), with 8 cases of COVID-19 (1 severe case) in the vaccine group and 162 cases (9 severe cases) in the…
Long-Term SARS-CoV-2 RNA Shedding and Its Temporal Association to IgG Seropositivity
A retrospective study juxtaposing longitudinal SARS-CoV-2 PCR positivity with IgG antibody seropositivity (n=851) found patients who seroconverted may still actively shed viral RNA. Out of 90 patients with positive IgG results (mean upper bound from initial PCR test = 37.8 days), 14 were actively shedding viral RNA (positive PCR test) between 0 and 64 days…
December 8, 2020
Defining the Features and Duration of Antibody Responses to SARS-CoV-2 Infection Associated with Disease Severity and Outcome
Analysis of 983 longitudinal plasma samples from 254 SARS-CoV-2 infected individuals with varying disease severity show that compared to severely ill patients, outpatients with mild illness had higher titers of IgG antibodies targeting the S1 domain or receptor binding domain (RBD) of the SARS-CoV-2 spike protein than of those targeting the nucleocapsid antigen. Neutralization assays…
SARS-CoV-2 Infection and COVID-19 Severity in Individuals with Prior Seasonal Coronavirus Infection
[Pre-print, not peer reviewed] Similar SARS-CoV-2 infection rates were observed between people with a prior PCR test for seasonal coronavirus that was positive (3.3%) or negative(3.1%) in a retrospective study among individuals with documented PCR testing for seasonal coronavirus and a subsequent PCR result for SARS-CoV-2 (n=2,768). The authors suggest this finding implies that past…
Safety and Efficacy of the ChAdOx1 NCoV-19 Vaccine (AZD1222) against SARS-CoV-2: An Interim Analysis of Four Randomised Controlled Trials in Brazil, South Africa, and the UK
An interim analysis of two of the four ongoing phase 2/3 trials for the Oxford–AstraZeneca chimpanzee adenovirus vectored vaccine ChAdOx1 nCoV-19 (n=7,548 in UK trial, n=4,088 in Brazil trial) showed a vaccine efficacy of 62.1% (95%CI 41.0-75.7%) among participants who received the planned two standard doses (27 COVID-19 cases among 4,440 in the vaccine group…
December 7, 2020
A Prospective Study on Rapidly Declining SARS‐CoV‐2 IgG Antibodies Within One to Three Months of Testing IgG Positive: Can It Lead to Potential Reinfections?
A prospective study of IgG antibody concentrations among 201 individuals in India who tested positive for SARS-CoV-2 found that only 28.4% of participants retained IgG antibody responses at 45-65 days follow-up. The authors highlight the need for future studies that use quantitative antibody assays and measure neutralizing antibody to assess risk of reinfection. Nag et…
While Studies on Covid‐19 Vaccine Is Ongoing; the Public’s Thoughts and Attitudes to the Future Covid‐19 Vaccine
Survey results from 759 adults in Turkey indicated that 49.7% of respondents said they would get a SARS-CoV-2 vaccine, and 38.4% said they would have their children vaccinated. Respondents cited the importance of protecting themselves, their children, and the people around them as the most common reasons they would get a vaccine. Common concerns about…
December 4, 2020
Durability of Responses after SARS-CoV-2 MRNA-1273 Vaccination
Immunogenicity data from 24 participants obtained at 119 days after initial vaccination (90 days after second vaccination) with the mRNA-1273 SARS-CoV-2 vaccine (Moderna) indicated that the vaccine produced high levels of binding and neutralizing antibodies that declined slightly over time, but remained elevated in all participants 3 months after the booster vaccination. Serum neutralizing antibodies…
December 3, 2020
International Estimates of Intended Uptake and Refusal of COVID-19 Vaccines A Rapid Systematic Review and Meta-Analysis of Large Nationally Representative Samples
[Pre-print, not peer reviewed] A systematic review and meta-analysis of 28 nationally representative samples from 13 countries (n=58,656) found that although a majority of people intend to be vaccinated for COVID-19, an increasing percentage of people are intending to refuse vaccination. Estimates of people intending to refuse vaccination rose from 12% in March-May to 20%…
Previous page Next page